---
name: tooluniverse-variant-interpretation
description: Systematic clinical variant interpretation from raw variant calls to ACMG-classified recommendations with structural impact analysis. Aggregates evidence from ClinVar, gnomAD, CIViC, UniProt, and PDB across ACMG criteria. Produces pathogenicity scores (0-100), clinical recommendations, and treatment implications. Use when interpreting genetic variants, classifying variants of uncertain significance (VUS), performing ACMG variant classification, or translating variant calls to clinical actionability.
---

# Clinical Variant Interpreter

Systematic variant interpretation using ToolUniverse - from raw variant calls to ACMG-classified clinical recommendations with structural impact analysis.

## Triggers

Use this skill when users:
- Ask about variant interpretation, classification, or pathogenicity
- Have VCF data needing clinical annotation
- Need ACMG classification for variants
- Want structural impact analysis for missense variants

## Key Principles

1. **ACMG-Guided** - Follow ACMG/AMP 2015 guidelines with explicit evidence codes
2. **Structural Evidence** - Use AlphaFold2 for novel structural impact analysis
3. **Population Context** - gnomAD frequencies with ancestry-specific data
4. **Actionable Output** - Clear recommendations, not just classifications
5. **English-first queries** - Always use English terms in tool calls; respond in user's language

---

## Workflow Overview

```
Phase 1: VARIANT IDENTITY        → Normalize HGVS, map gene/transcript/consequence
Phase 2: CLINICAL DATABASES       → ClinVar, gnomAD, OMIM, ClinGen, COSMIC, SpliceAI
Phase 2.5: REGULATORY CONTEXT     → ChIPAtlas, ENCODE (non-coding variants only)
Phase 3: COMPUTATIONAL PREDICTIONS → CADD, AlphaMissense, EVE, SIFT/PolyPhen
Phase 4: STRUCTURAL ANALYSIS      → PDB/AlphaFold2, domains, functional sites (VUS/novel)
Phase 4.5: EXPRESSION CONTEXT     → CELLxGENE, GTEx tissue expression
Phase 5: LITERATURE EVIDENCE      → PubMed, EuropePMC, BioRxiv, MedRxiv
Phase 6: ACMG CLASSIFICATION      → Evidence codes, classification, recommendations
```

---

## Phase 1: Variant Identity

Tools: `myvariant_query`, `Ensembl_get_variant_info`, `NCBI_gene_search`

Capture: HGVS notation (c. and p.), gene symbol, canonical transcript (MANE Select), consequence type, amino acid change, exon/intron location.

## Phase 2: Clinical Databases

Tools: `clinvar_search`, `gnomad_search`, `OMIM_search`, `OMIM_get_entry`, `ClinGen_search_gene_validity`, `ClinGen_search_dosage_sensitivity`, `ClinGen_search_actionability`, `COSMIC_search_mutations`, `COSMIC_get_mutations_by_gene`, `DisGeNET_search_gene`, `DisGeNET_get_vda`, `SpliceAI_predict_splice`, `SpliceAI_get_max_delta`

Use SpliceAI for: intronic variants near splice sites, synonymous variants, exonic variants near splice junctions.

See `CODE_PATTERNS.md` for implementation details.

## Phase 2.5: Regulatory Context (Non-Coding Only)

Apply for intronic (non-splice), promoter, UTR, or intergenic variants near disease genes.

Tools: `ChIPAtlas_enrichment_analysis`, `ChIPAtlas_get_peak_data`, `ENCODE_search_experiments`, `ENCODE_get_experiment`

## Phase 3: Computational Predictions

Tools: `CADD_get_variant_score` (PHRED 0-99), `AlphaMissense_get_variant_score` (0-1, needs UniProt ID), `EVE_get_variant_score` (0-1), `myvariant_query` (SIFT/PolyPhen), `Ensembl_get_variant_info` (VEP)

Consensus: Run CADD (all variants) + AlphaMissense + EVE (missense). 2+ concordant damaging = strong PP3; 2+ concordant benign = strong BP4.

See `ACMG_CLASSIFICATION.md` for thresholds.

## Phase 4: Structural Analysis (VUS/Novel Missense)

Tools: `PDB_search_by_uniprot`, `NvidiaNIM_alphafold2`, `alphafold_get_prediction`, `InterPro_get_protein_domains`, `UniProt_get_protein_function`

Workflow: Get structure -> map residue -> assess domain/functional site -> predict destabilization.

## Phase 4.5: Expression Context

Tools: `CELLxGENE_get_expression_data`, `CELLxGENE_get_cell_metadata`, `GTEx_get_median_gene_expression`

Confirms gene expression in disease-relevant tissues. Supports PP4 if highly restricted; challenges classification if not expressed in affected tissue.

## Phase 5: Literature Evidence

Tools: `PubMed_search`, `EuropePMC_search`, `BioRxiv_search_preprints`, `MedRxiv_search_preprints`, `openalex_search_works`, `SemanticScholar_search_papers`

Always flag preprints as NOT peer-reviewed.

## Phase 6: ACMG Classification

Apply all relevant evidence codes (PVS1, PS1, PS3, PM1, PM2, PM5, PP3, PP5 for pathogenic; BA1, BS1, BS3, BP4, BP7 for benign). See `ACMG_CLASSIFICATION.md` for the complete algorithm.

---

## Special Scenarios

**Novel Missense VUS**: Check PM5 (other pathogenic at same residue), get AlphaFold2 structure, apply PM1/PP3 as appropriate.

**Truncating Variant**: Check LOF mechanism, NMD escape, alternative isoforms, ClinGen LOF curation. Apply PVS1 at appropriate strength.

**Splice Variant**: Run SpliceAI, assess canonical splice distance, in-frame skipping potential. Apply PP3/BP7 based on scores.

---

## Output Structure

```markdown
# Variant Interpretation Report: {GENE} {VARIANT}
## Executive Summary
## 1. Variant Identity
## 2. Population Data
## 3. Clinical Database Evidence
## 4. Computational Predictions
## 5. Structural Analysis
## 6. Literature Evidence
## 7. ACMG Classification
## 8. Clinical Recommendations
## 9. Limitations & Uncertainties
## Data Sources
```

File naming: `{GENE}_{VARIANT}_interpretation_report.md`

---

## Clinical Recommendations

**Pathogenic/Likely Pathogenic**: Enhanced screening, risk-reducing options, drug dosing adjustment, reproductive counseling, family cascade screening.

**VUS**: Do not use for medical decisions. Reinterpret in 1-2 years. Pursue functional studies and segregation data.

**Benign/Likely Benign**: Not expected to cause disease. No cascade testing needed.

---

## Quantified Minimums

| Section | Requirement |
|---------|-------------|
| Population frequency | gnomAD overall + at least 3 ancestry groups |
| Predictions | At least 3 computational predictors |
| Literature search | At least 2 search strategies |
| ACMG codes | All applicable codes listed |

---

## References

- `ACMG_CLASSIFICATION.md` - Evidence codes, classification algorithm, prediction thresholds, structural/regulatory impact tables
- `CODE_PATTERNS.md` - Reusable code patterns for each workflow phase
- `CHECKLIST.md` - Pre-delivery verification
- `EXAMPLES.md` - Sample interpretations
- `TOOLS_REFERENCE.md` - Tool parameters and fallbacks
